STARODUBOV, V.I.,
MARCZAK, L.B.,
VARAVIKOVA, E.,
BIKBOV, B.,
ERMAKOV, S.P.,
GALL, J.,
GLENN, S.D.,
GRISWOLD, M.,
IDRISOV, B.,
KRAVCHENKO, M.,
LIOZNOV, D.,
LOYOLA, E.,
RAKOVAC, I.,
VLADIMIROV, S.K.,
VLASSOV, V.,
MURRAY, C.J.L.,
NAGHAVI, M (2018) with
disability (YLDs), years of life lost (YLLs),
disability-adjusted life-years (DALYs), and associated risk
ANATOMIC MESOHEPATECTOMY VERSUS EXTENDED HEPATECTOMY FOR PATIENTS WITH CENTRALLY LOCATED HEPATOCELLULAR CARCINOMA for these patients by multivariable regression analysis. In addition, the patients in the MH
group were matched in a
CONNORS, J.M.,
SAVAGE, K.J,
JURCZAK, W,
LECH-MARANDA, E.,
SMOLEWSKI, P,
WALEWSKI, J,
STRAUS, D.J.,
YOUNES, A.,
ANSELL, S.M.,
KIM, W.S.,
GALLAMINI, A.,
ALEKSEEV, S.,
ILLÉS, A.,
ROSTA, A.,
PICARDI, M.,
ZINZANI, P.L.,
OKI, Y.,
FELDMAN, T.,
BARTLETT, N.L.,
CHEN, R.,
RAMCHANDREN, R.,
CUNNINGHAM, D.,
RADFORD, J.,
JOSEPHSON, N.C.,
SONG, E.,
SACHS, J.,
JOLIN, H.A.,
HUEBNER, D.,
LIU, R.,
LIPATOV, O.N. (2018) modified progression-free survival rates
in the A+AVD and ABVD
groups were 82.1% (95% confidence interval
Salimova, E.V.,
Mamaev, A.G.,
Tret'yakova, E. V.,
Kukovinets, O. S.,
Mavzyutov, A. R.,
Shvets, K. Yu.,
Parfenova, L. V. (2018) of addition of two cyanoethyl
groups to the -position with respect to the C-3=O carbonyl
group. The isolated
Тиетанильная защита в синтезе 5-арилокси (сульфонил) -3-бром-1,2,4-триазоловKhaliullin, F.A.,
Klen, E. E.,
Makarova, N. N.,
Халиуллин, Ф.А.,
Клен, Э.,
Макарова, Н. Н. (2018) , nucleophilic substitution of the 5-bromine atom by phenoxy or phenylsulfanyl
group, oxidation of the thietane